Generated by AI
Ensysce Biosciences, Inc. Common Stock represents ownership in Ensysce Biosciences, Inc., a clinical-stage biopharmaceutical company focused on developing prescription therapies for severe pain and central nervous system conditions. The company’s current work centers on proprietary drug-delivery and abuse-deterrence platforms, including Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR), which are designed to improve how certain medications are activated and to reduce the risks of misuse, abuse, and overdose. Its pipeline includes candidates for pain management, opioid protection, and attention deficit hyperactivity disorder, reflecting a focus on controlled pharmaceutical innovation rather than broad commercial medicines. Based in La Jolla, California, Ensysce Biosciences operates in the biotechnology and pharmaceuticals segment of the healthcare market, where it contributes to research-driven solutions aimed at safer treatment options for patients and clinicians.
Website7946 Ivanhoe Avenue
La Jolla, CA, 92037
United States
The latest articles about ENSC.
~President James Morrison met Middle East family offices as Ensysce advances CY200 and its severe pain pipeline~SAN DIEGO, CA / ACCESS Newswire / October 21, 2026 / , Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage biotechnology company developing innovative neuroplastogenic therapies beyond mood disorders, with an initial focus on Complex Regional Pain Syndrome ("CRPS") today announced that James Morrison, President of , participated in the Family Office Summit, Dubai, on Octo
Summary of Nov 13's posts. Generated by AI.
Summary of Aug 14's posts. Generated by AI.
Summary of Aug 6's posts. Generated by AI.
Summary of Oct 9's posts. Generated by AI.
Investors talking about ENSC also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.